Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 15,001–15,100 of 15,747
Wang, S., Jing, S., Zou, S., Zhang, Y., Ge, M., Gao, K., Li, X., Zhao, L., & Wang, J. (2026) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70160
“The remarkable success of mRNA vaccines during the COVID-19 pandemic has accelerated the maturation of mRNA vaccine technology, 33,34 promoting its broader application in cancer research and offering a promising avenue for cancer prevention and treatment. this hypofractionated approach aligns with…”
Drugs against broad-spectrum of coronaviruses
Huang, S., Zhang, X., Luo, W., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1728474
Yu, M., Wang, L., Liu, D., Guo, J., Liu, J., Zhou, J., Mathew, A., He, Z., Wu, J., & Zhang, N. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103483 · Cited by 2
Impfen bei pneumologischen Erkrankungen – was, wann und wie?
Kodde, C., & Sander, L. E. (2024) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2115-0404
Barmeyer, C., & Rath, C. R. (2024) · Springer eBooks · doi:10.1007/978-3-658-30555-0_9 · Cited by 1
Kim, R., Uhm, T.-G., Kim, J., Woo, D., Kim, U.-I., Meng, X. W., Yang, B., Kim, S., Kim, H.-R., Kim, J., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1571092 · Cited by 1
Saeed, B. Q., Adrees, A. O., Fahady, K. S., et al. (2023) · Advances in Biomedical and Health Sciences · doi:10.4103/abhs.abhs_12_23
Ochando, J., Cámara, C., Durham, L., Sempere, J. M., & López‐Hoyos, M. (2022) · Current Research in Immunology · doi:10.1016/j.crimmu.2022.06.001
“severe COVID-19 disease in individuals from 16 years old and older (Polack et al., 2020).”
BackgroundMögliche Geschwindigkeit und Bedeutung biomedizinischer Forschung
Welz, A. (2021) · Zeitschrift für Herz- Thorax- und Gefäßchirurgie · doi:10.1007/s00398-020-00415-w
Protecting Our Most Vulnerable: Vaccine Responses in Patients With Blood Cancers
Lane, M. J., & Lane, S. (2021) · The Hematologist · doi:10.1182/hem.v18.6.202163
The impact of COVID-19 on patients with heart failure and valvular disease
Portera, M. V., DONALD, E. M., Ranard, L. S., & DeFilippis, E. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14001-3.00013-3
Targeted degradation of PCNA outperforms stoichiometric inhibition to result in programed cell death
Chang, S. C., Gopal, P., Lim, S., Wei, X., Chandramohan, A., Mangadu, R., Smith, J., Ng, S., Gindy, M., Phan, U., et al. (2022) · doi:10.1101/2022.01.29.478266 · Cited by 31
Eviatar, T., Ziv, A., Oved, A., Miller‐Barmak, A., Pappo, A., Livny, R., Amarilyo, G., Aviel, Y. B., Naor, R., Pel, S., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126426
Wanchaijiraboon, P., Sainamthip, P., Teeyapun, N., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4189404
Gurkšnienė, V., Alčauskas, T., Karosiene, D., Urbonienė, J., Majauskaitė, F., Paulauskas, M., Zablockienė, B., Vitkus, D., & Jančorienė, L. (2026) · Medicina · doi:10.3390/medicina62050810 · Cited by 1
“Further studies have shown that two doses of the BNT162b2 vaccine provide 95% protection against COVID-19 in people over 16 years of age [10].”
Aoyagi, T. (2026) · Kansenshogaku zasshi · doi:10.11150/kansenshogakuzasshi.r25002
Hart, D. (2021) · Medizinrecht · doi:10.1007/s00350-021-5944-5
Gadelha, C. S. E., Terreri, M. T., Burian, A. P. N., da Fraga, A. C. M., Machado, K. L. L. L., Silva, R. E. C. D. F., Ferreira, D. B., Moraes, Y. O. G., Ribeiro, S. L. E., Telles, C. M. P. F., et al. (2026) · Pediatric Research · doi:10.1038/s41390-026-04836-5
COVID-19 In United States: Statistical Analysis and Inferences From the Empirical DataPreprint
Rethnakar, N. (2021) · Research Square · doi:10.21203/rs.3.rs-1084057/v1
Shimazu, Y., Miyoshi, T., Mibayashi, S., Kazuma, Y., Kobayashi, M., Shindo, K., & Imashuku, S. (2023) · Oncology Advances · doi:10.14218/ona.2023.00022
Cardioprotective effects of vaccination in hospitalized patients with COVID-19
Madrid, J., Agarwal, P., Müller‐Peltzer, K., Benning, L., Selig, M., Rolauffs, B., Diehl, P., Kalbhenn, J., Trummer, G., Utzolino, S., et al. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01367-3 · Cited by 4
“Research has demonstrated that COVID-19 vaccination is effective in preventing infection from the virus [12, 13].”
Embracing Controversy: A Second Look at CDC Reform Efforts in the Wake of COVID-19
Keller, A. C. (2024) · Journal of Health Politics Policy and Law · doi:10.1215/03616878-11672932
Vaccination against Covid-19: contribution to therapy and prognosis
Kartashova, M., Kiseleva, Y., Semenistaya, M. C., & Pavlov, C. (2021) · Медицинская этика · doi:10.24075/medet.2021.017
“The mean age was 52 years; 42% of the participants were older than 55 years [18].”
BackgroundInfluential(2021) · doi:10.1101/2021.06.18.21258477
“This can be 138 achieved through viral infection [1] or by vaccination [2-4].”
BackgroundSow, S. O., Tapia, M. D., Haidara, F. C., Diallo, F., Xi, H., Chen, J., Shi, L., Yang, Q. K., Yu, B., Hu, Y., et al. (2024) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2024.107237 · Cited by 1
Perrig, L., Abela, I. A., Banholzer, N., Audigé, A., Epp, S., Mugglin, C., Zürcher, K., Egger, M., Trkola, A., & Fenner, L. (2023) · Swiss Medical Weekly · doi:10.57187/s.3502
Streiber, M., Liu, N., Simon, L., Adermann, F., Bachmann, V., Hoeppener, S., Schubert, S., Werz, O., Lapinte, V., Morille, M., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5200072
Etiological Profile of Epistaxis: Pre-Pandemic Versus Pandemic.
Vlăescu, A. N., Ionita, E., Anghelina, F., Mogoanta, C. A., Ciolofan, S.-M., Rusescu, A., Ioniță, I.-G., Voiosu, C., & Hainăroșie, R. (2023) · PubMed Central · doi:10.12865/chsj.49.03.08 · Cited by 1
Ipsilateral Upper-Limb Lymphedema After COVID-19 Vaccine Booster: Reply
Tang, C. Y. L., & Chua, W. M. (2023) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000004741
Spatial Tail Design in Ionizable Lipids Enhances the Safety and Efficacy of mRNA Delivery
Li, H., Tian, C., Kong, W., Weiss, J., Gang, J., Zhong, T., Ma, Y., Xu, J., Tai, W., Zeng, F., et al. (2026) · Small Methods · doi:10.1002/smtd.70796
“Among these, lipid nanoparticles (LNPs) stand out as the most extensively utilized mRNA delivery vehicles [ 12–14 ].”
Effectiveness of COVID-19 vaccines: A systematic review
Sony, P., Kannan, I., & Thenmozhivalli, P. R. (2023) · Asian Journal of Medical Sciences · doi:10.3126/ajms.v14i11.55746
Bürzle, O., Menges, D., Maier, J. D., et al. (2022) · medRxiv · doi:10.1101/2022.09.27.22280403
Riaba, O. V., & Анастасій, І. А. (2025) · Інфекційні хвороби · doi:10.11603/1681-2727.2025.1.15152
Biocompatible Nanocomposites for Vaccine Delivery
Rajakumari, R., Sangeetha, G., Kalarikkal, N., & Thomas, S. (2025) · Advanced structured materials · doi:10.1007/978-981-96-7450-3_9
Self-citationFan, C., Cohen, A. A., Dam, K.-M. A., Rorick, A. V., Fils, A.-C. I. P., Yang, Z., Gnanapragasam, P. N. P., Segovia, L. N., Huey‐Tubman, K. E., Moon, W. J., et al. (2026) · eLife · doi:10.7554/elife.108959.2 · Cited by 1
Hu, Y., Weng, Y., Li, X., Huang, Y., Pan, J., Wu, Y., Liao, R., Gong, R., Zhao, L., Zhang, D., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1801564
Tomanguillo, J., Searls, L., Annie, F., Kemper, S. E., & Naravadi, V. V. R. (2023) · Cureus · doi:10.7759/cureus.34004
Ghebrehewet, S., Stewart, A., & MacPherson, P. (2024) · Public Health · doi:10.1016/j.puhe.2024.05.002
Ogura, W., Ohtsuka, K., Matsuura, S., Okuyama, T., Matsushima, S., Yamasaki, S., Miyagi, H., Sekiguchi, K., Ohnishi, H., & Watanabe, T. (2022) · Viruses · doi:10.3390/v14050956
“The BNT162b2 mRNA vaccine (Pfizer–BioNTech) is highly effective at preventing clinically significant COVID-19 [8–11], reducing the incidence of asymptomatic infection and Viruses 2022, 14, 956. https://doi.org/10.3390/v14050956 https://www.mdpi.com/journal/viruses Viruses 2022, 14, 956 2 of 8 associated infectivity [1…”
BackgroundInfluentialArtificial intelligence (AI)-enabled platforms for cancer vaccine engineering
Mali, A. K., Das, S. S., & Thorat, N. D. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104785
The (Contrasted) Ethics of Covid-19 and HIV: Will the Favor be Returned?
Campbell, H. E., Abdul‐Mutakabbir, J. C., & Hodge, D. A. (2021) · PubMed
Long COVID: A Case Report of Long SARS-CoV-2 for One Year
Mottaghi-Dastjerdi, N., Yadollahzadeh, M., Farasatinasab, M., et al. (2024) · Coronaviruses · doi:10.2174/0126667975286263240321050916
Ackland, J., Barozi, V., Penrice-Randal, R., Hartley, C., Hiscox, J., Griffiths, G., Page, C. P., Carroll, M. W., Singh, D., Niranjan, M., et al. (2026) · Journal of Immunology · doi:10.1093/jimmun/vkag189
Abdelkader, H. S., Rifaat, M., Baghdadi, M. A., Sindi, N., & Rifaat, R. M. (2021) · Dr Sulaiman Al Habib Medical Journal · doi:10.2991/dsahmj.k.211103.001
Understanding COVID-19 Vaccine Education for Long-Term Care Workers: An Environmental Scan
Ramzy, A., Reed, A. C., Murmann, M., Heer, C., May, K., Scott, M., Welch, V. A., Wilson, K. R., Little, J., Presseau, J., et al. (2023) · Canadian Nurse Practitioner Journal · doi:10.28984/npoj.v3i2.416 · Cited by 1
COVID-19 - O VÍRUS QUE MOVIMENTOU A CIÊNCIA - VOLUME 1
Almeida, P. D., de Araújo, T. M. E., Brandão, S. A. D. S. M., Sena, I. V. D. O., Rodrigues, É. D. A., Costa, J., Fronteira, I., Cardoso, J. A., Júnior, E. B. D. M., Almeida, M. G., et al. (2021) · Editora Pasteur eBooks · doi:10.29327/533647
The Techniques Used on the Development of COVID-19 Vaccine
Su, J. (2021) · E3S Web of Conferences · doi:10.1051/e3sconf/202127101037
Selbstbestimmungsaufklärung und Pandemiebekämpfung
Drechsler, J. (2021) · Medizinrecht · doi:10.1007/s00350-021-5878-y
The Challenge of Evaluating Vaccine Safety and Effectiveness
Mueller, S. (2022) · Springer eBooks · doi:10.1007/978-3-031-18903-6_5
Clinical characteristics, management, and prevention of coronavirus disease 2019
Guan, W., & He, J. (2023) · Frigid Zone Medicine · doi:10.2478/fzm-2023-0019
“…of these vaccines, while a single dose typically elicits modest immune response [77,86,89, 212-236 Two-dose vaccine has been reported to range from 66.7% to 95% in the general population [77,216,218-220, 230-231 230-231 ] , except for the lower efficacy of chimpanzee adenovirus vaccine [ 89] .”
InfluentialOccipital neuralgia after COVID-19 vaccination: a report of two casesPreprint
Malheiro, S. F., Costa, D., & Varela, R. (2023) · Research Square · doi:10.21203/rs.3.rs-2478283/v1
Wettengel, J. M., Strehle, K., von Lucke, C., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.01768-23
Duh, M. S., Nguyen, C., Rubino, H., Herrick, C. D., Chang, R., DerSarkissian, M., Hsieh, Y. G., Banatwala, A., Yu, L., Belsky, G., et al. (2023) · medRxiv · doi:10.1101/2023.09.12.23295441
Sinclair, R. C., & Melton, R. J. (2022) · Research Square · doi:10.21203/rs.3.rs-1277705/v1
Decoding Self vs. Non-Self: Alphavirus Cap0 Recognition and Immune Evasion
Faraj, S. E., & Filomatori, C. V. (2026) · Viruses · doi:10.3390/v18040439 · Cited by 2
“Such innova‑ tions were central to the success of mRNA vaccines against SARS‑CoV‑2 [80,81] and offer a valuable framework for the development of next‑generation vaccines targeting other RNA viruses [82].”
Screening of Omicron Virus Strain by Quantifying the Spike Protein Content
He, Z., Chang, H., Wang, Y., Xie, S., Liu, Y., Zhao, Y., Li, N., & Zhang, Y. (2024) · COVID · doi:10.3390/covid4060056
“…way to prevent COVID-19 [10], and the current COVID-19 vaccine candidates are mainly based on the following technical routes: inactivated virus vaccines [11,12], protein subunit vaccines [13,14], mRNA vaccines [15,16], and viral vector vaccines [17], such as the adenoviral vector vaccine [18,19].”
BackgroundInfluentialSpires, S. S., Clark, J., Rayburn-Reeves, R. M., Ashley, E. D., Desai, A. P., & Lindemans, J. W. (2022) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2022.50
“(1) Process safety: Rapid development and testing of COVID-19 vaccines were made possible through a combined effort worldwide and vaccines are both safe and effective.”
BackgroundIshikawa, U., Mabrouk, M. T., & Yang, Y. (2026) · ACS Nano Medicine · doi:10.1021/acsnanomed.5c00166
Chong‐Silva, D. C., Pastorino, A. C., Anna, M. D. F. B. P. S., et al. (2020) · Arquivos de Asmas Alergia e Imunologia · doi:10.5935/2526-5393.20200044
Inflammation and Heart Failure
Kim, K., Kim, D., & Eisen, H. J. (2026) · Springer eBooks · doi:10.1007/978-3-032-12629-0_20
López, A. I. P., Ramal, S. L., Barrachina, S. S., et al. (2023) · Revista de Lactancia Materna · doi:10.14201/rlm.30761
EVENTOS ADVERSOS DAS VACINAS CONTRA COVID-19 EM UM ESTADO DO NORDESTE BRASILEIRO
Chaves, A. F. D. C. P., de Araújo, T. M. E., BEZERRA, G. S. S., de Araújo, O. D., Vieira, C. P. D. B., & Pereira, B. M. (2025) · Enfermagem em Foco · doi:10.21675/2357-707x.2025.v16.e-2025080
A Comprehensive Review on Covid-19 Variants
Asra, S., Anusha, C. V., Ahalya, M. T., Rehman, A., & Suman, P. (2022) · International Journal for Research in Applied Science and Engineering Technology · doi:10.22214/ijraset.2022.47073
Graham, J. P., Arteaga, A., Moghaddam, A. S., Spiller, K. L., Laverty, D. J., & Gonzalez‐Fernandez, T. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.29.728905 · Cited by 1
“21,22 Yet, LNPs are inherently immunogenic, helping to mount a response to the delivered spike protein and initiate antibody production.”
Zhu, Q., Gao, J., Gu, J., Shen, L. H., Liu, J., Song, Y., Gong, X., Chen, Y., Liao, J., He, Y., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3936498
Tan, C. C., Zakaria, N. S., Yusop, Y. M., & Abdrahim, N. A. (2021) · International Journal of Academic Research in Business and Social Sciences · doi:10.6007/ijarbss/v11-i8/10696
Evaluating Spike Antigenicity across Endemic Human Coronavirus Models using Flow VirometryPreprint
Burnie, J., Ouano, C., Luo, V., Dzuvor, C. K. O., Miller, T., Ospina, G., Tanneti, N. S., Tan, L. H., Hamel, D. J., Hammond, C., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.28.728498
Jameie, M., Looha, M. A., Ebadi, Z., Amanollahi, M., Amani, K., Nobahari, F., Abdollahi, A., Mousavi, M., Pourghaz, B., & Harirchian, M. H. (2024) · BMC Neurology · doi:10.1186/s12883-024-03793-y · Cited by 1
Ongun, M., Kola, N. S., Patel, D., Rodrigues, T. C., Schmidt, S., Lokras, A. G., Franzyk, H., Paludan, S. R., Rades, T., Thakur, A., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-60179-5
Kustova, D. D., Pochtovyi, A. A., Геннадьевна, Ш. О., Shtinova, I. A., Kuznetsova, N. A., Клейменов, Д. А., Komarov, A. G., & Gushchin, V. А. (2024) · Problems of Virology · doi:10.36233/0507-4088-242
Probióticos – uma espada ou um escudo no desfecho da COVID-19?
de Abreu, J. A. C., de Freitas, N. L., AZEVEDO, P. R. G., & Brandão, F. (2022) · Research Society and Development · doi:10.33448/rsd-v11i4.27165 · Cited by 1
Morel, J., & Richez, C. (2021) · Revue du Rhumatisme Monographies · doi:10.1016/j.monrhu.2021.11.002
Qin, R., Luo, Y., Zhou, Z., Xu, Y., Wu, X., 侯燕群, Chen, J., Zhu, F., & Pan, P. (2026) · Pharmaceutical Research · doi:10.1007/s11095-026-04192-3
Personalized medicine and genetic newborn screening
Brusa, M., & Dickenson, D. L. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.003.0008 · Cited by 1
A single-nucleotide change in the Kozak sequence enhances protein expression from IVT mRNA
Knol, R. A., Fariaby, T., de Vlieger, E. A., van Santbrink, P., Kros, A., & Slütter, B. (2026) · Molecular Therapy — Nucleic Acids · doi:10.64898/2026.05.20.726450
Sadigh, K. S., Kugeler, K. J., Bressler, S. S., Massay, S., Schmoll, E., Milroy, L., Cavanaugh, A. M., Sierocki, A., COVID-19 Vaccine Breakthrough Characterization Team, Dorough, L., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07702-x · Cited by 1
Clinical Translation of Smart Nanomaterials
Mariappan, V., & Moorthi, P. V. (2026) · Springer eBooks · doi:10.1007/978-981-95-9386-6_15 · Cited by 1
Meyers, E., Rop, L. D., Deschepper, E., Duysburgh, E., Burghgraeve, T. D., Ngoc, P. V., Digregorio, M., Coen, A., Clercq, N. D., Wallaert, S., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.126865 · Cited by 2
Wu, X., Liang, C., Lei, Y., Peng, X., Zhang, Y., Yang, G., Yin, H., & Xu, K. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.22.550185
Editorial: COVID-19 immunology and organ transplantation
Bery, A. I., Kulkarni, H. S., & Kreisel, D. (2021) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000862 · Cited by 1
Next‐Generation Bio‐Reducible Lipids Enable Enhanced Vaccine Efficacy in Malaria and Primate Models
Coen, R. D., Kasmi, S., Dumbre, S. G., Baekens, L., Seynaeve, E., den Hauwe, L. V., Cantini, N., Garantoudi, A., Madeira, F. B., Marrot, A., et al. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202509838 · Cited by 4
Lu, Z., Lu, Y., Liu, D., Du, F., Wu, Q., Liao, G., Wu, Y., Zhang, R.-L., Zhou, J., & Wang, Q. (2026) · Emerging Microbes & Infections · doi:10.1080/22221751.2026.2685927 · Cited by 1
“Furthermore, clinically licensed COVID-19 mRNA vaccines, such as BNT162b2 and mRNA-1273, are administered at fixed microgram doses (30 and 100 µg per dose in adults, respectively) rather than using strict body-weight-based scaling [27, 28].”
Talk of the town in 2021: Covid‐19 vaccines likely take centre stage
Höglund, P. (2020) · Scandinavian Journal of Immunology · doi:10.1111/sji.13014
"Pfizer/Biontech Post Vaccine Acute St-Elevation Myocardial Infarction: A Case"
Coşkun, A. (2021) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2021.40.006495
“Although vaccines dedicated to COVID-19 disease have been approved as safe, both the disease and the vaccine are relatively new [4-6].”
BackgroundAbouammoh, N. A. (2026) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1054_25
“[1,2] Large‑scale immunization in countries such as Brazil, India, China, and the United States significantly decreases COVID‑19 deaths and transmission, underscoring vaccination’s impact as a public health measure.”
Ricke, D. O. (2022) · Research Square · doi:10.21203/rs.3.rs-1702797/v1
Considerations for Coronavirus Disease 2019 Vaccination Among B-Cell-Depleted Patients
Ammitzbøll, C. G., Thomsen, M. K., Erikstrup, C., & Troldborg, A. (2024) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2024.09.006 · Cited by 1
Bioengineering strategies to interrogate and modulate the aging immune system
Nikolich‐Žugich, J., Wolf, M. T., Pompano, R. R., & Maisel, K. (2026) · Nature Aging · doi:10.1038/s43587-026-01187-y
Bayesian uncertainty quantification to identify population level vaccine hesitancy behaviours
Warne, D. J., Varghese, A., Brewster, A., Browning, A. P., Krell, M. M., Drovandi, C., Hu, W., Mira, A., Mengersen, K. L., & Jenner, A. L. (2026) · PLoS ONE · doi:10.1371/journal.pone.0349499
“By January 2021, two COVID-19 vaccines with greater than 90% efficacy to reduce symptomatic infection risk were approved in the EU (Polack et al., 2020; Baden et al., 2021).”
Elkousy, H. A., Khoriaty, J. D., Vidal, E. A., et al. (2022) · JSES Reviews Reports and Techniques · doi:10.1016/j.xrrt.2021.12.003
Impact of New COVID-19 Variant on Stroke, Thrombosis and Neurological Impairment
Das, R., Agrawal, S., Singh, N., Singh, K., & Tripathi, A. K. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002798
Mogollon, J., Halaseh, G., & Swaminathan, N. (2023) · Contemporary Endocrinology · doi:10.1007/978-3-031-28536-3_1 · Cited by 1
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.